Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 18, 2026 07:18 ET | Source: Research and Markets

Life Science Instrumentation Market Forecast Report 2025-2031: Expanding Activities in Genomics, Proteomics, and Drug Discovery with Thermo Fisher Scientific, Danaher, Agilent, and Shimadzu Leading

Dublin, May 18, 2026 (GLOBE NEWSWIRE) -- The "Life Science Instrumentation Market by Technology, Application, End User - Global Forecast to 2031" has been added to ResearchAndMarkets.com's...
May 17, 2026 15:30 ET | Source: Novartis Pharma AG

New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer

More durable, deeper PSA response in patients treated with Pluvicto plus standard of care (ARPI + ADT) vs. SoC aloneDeep PSA reduction higher in patients receiving Pluvicto combination vs. SoC at 12,...
May 06, 2026 09:19 ET | Source: Research and Markets

Opportunity Insights for the $1.1 Billion Preclinical Imaging Industry, 2026 - Bruker Corp., Cubresa, and Siemens Healthineers Lead

Dublin, May 06, 2026 (GLOBE NEWSWIRE) -- The "Preclinical Imaging Industry Analysis, Size, Share, Growth, Trends, and Forecast 2026-2033 - (by Product Type, Application, End-User, Geographic...
April 07, 2026 12:01 ET | Source: Research and Markets

Messenger RNA (mRNA) Market Projected to Reach $20.99 Billion by 2035 - Moderna, Pfizer, and Others Propel mRNA Expansion into New Therapeutic Areas

Dublin, April 07, 2026 (GLOBE NEWSWIRE) -- The "Messenger RNA Market - A Global and Regional Analysis: Application and Regional Analysis - Analysis and Forecast, 2025-2035" has been added to ...
February 25, 2026 07:00 ET | Source: Novartis Pharma AG

Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients

Facility expected to be operational in 2028 in Dallas-Fort Worth area, expanding largest RLT manufacturing network in USSite to serve patients in Southern US and add network capacity as RLT expands...
February 25, 2026 07:00 ET | Source: Novartis Pharma AG

Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients

Facility expected to be operational in 2028 in Dallas-Fort Worth area, expanding largest RLT manufacturing network in USSite to serve patients in Southern US and add network capacity as RLT expands...
February 24, 2026 07:15 ET | Source: Novartis Pharma AG

New real‑world data reinforce earlier use of Pluvicto™ before chemotherapy in metastatic castration-resistant prostate cancer

In the real-world, Pluvicto™ showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPCReal‑world evidence showed Pluvicto achieved longer PFS when initiated after one ARPI instead...
February 06, 2026 12:00 ET | Source: Novartis Pharma AG

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing global research sites including Cambridge, Massachusetts, and Basel,...
February 06, 2026 12:00 ET | Source: Novartis Pharma AG

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing global research sites including Cambridge, Massachusetts, and Basel,...
February 03, 2026 07:44 ET | Source: Research and Markets

Cell-Based Assay & High Content Screening Research Report 2026: Market Forecasts 2025-2029 - Expanding Candidate Pipelines, Immuno-Oncology Focus, and Technology Convergence Bolster Growth

Dublin, Feb. 03, 2026 (GLOBE NEWSWIRE) -- The "Cell-Based Assay & High Content Screening Market 2025-2029 - Forecasts by User and Product, with Executive and Consultant Guides" report has been...